RxDoctor Payments Data

Nadia El Hangouche, MD

Cardiovascular Disease · Cincinnati, OHNPI 1700134087

Payments from drug & device makers

$5,866in general payments, 2019–2025

Across 59 payments — averaging $99.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Abbott$2K
  • Medtronic$1K
  • Boston Scientific$244
  • Jenavalve Technology, Inc.$175
  • Sanofi$104
  • plus $120 from 3 others

What the payments were for

  • Consulting fees$1753%
  • Speaking & faculty fees$87515%
  • Travel & lodging$2,19737%
  • Food & beverage$2,56844%
  • Education$501%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,866 in reported general payments places this provider in the 70th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$147,501
Medicare patients
1,387
Services billed
2,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban281$259,063
EntrestoSacubitril/Valsartan165$138,447
Repatha SureclickEvolocumab76$71,638
XareltoRivaroxaban67$55,931
Praluent PenAlirocumab43$40,323
JardianceEmpagliflozin33$32,780
Repatha SyringeEvolocumab15$11,577
BrilintaTicagrelor16$11,199
FarxigaDapagliflozin Propanediol13$7,225
Nifedipine ErNifedipine238$5,216
Metoprolol Succinate420$5,055
Rosuvastatin Calcium275$2,129
Ezetimibe88$1,702
Pantoprazole Sodium145$1,695
Atorvastatin Calcium189$1,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$259,063281 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →